Jeremy Greene
#171,985
Most Influential Person Across History
Researcher
Jeremy Greene's AcademicInfluence.com Rankings
Jeremy Greeneengineering Degrees
Engineering
#9978
Historical Rank
Biomedical Engineering
#873
Historical Rank
Jeremy Greenecomputer-science Degrees
Computer Science
#11021
Historical Rank
Informatics
#79
Historical Rank
Database
#8860
Historical Rank
Download Badge
Engineering Computer Science
Jeremy Greene's Degrees
- Bachelors Biomedical Engineering Stanford University
Why Is Jeremy Greene Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jeremy A. Greene is the William H. Welch Professor of Medicine and the History of Medicine, at Johns Hopkins University. Career Greene is a professor of Medicine and History of Medicine at Johns Hopkins School of Medicine. Greene has studied the generic drug industry. His work appears in Slate.
Jeremy Greene's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Online Social Networking by Patients with Diabetes: A Qualitative Evaluation of Communication with Facebook (2011) (728)
- Assessing the Gold Standard--Lessons from the History of RCTs. (2016) (404)
- Prescribing by Numbers: Drugs and the Definition of Disease (2007) (286)
- The burden of disease and the changing task of medicine. (2012) (264)
- A contact dermatitis of broilers -clinical and pathological findings. (1985) (211)
- Hidden in plain sight marketing prescription drugs to consumers in the twentieth century. (2010) (127)
- Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. (2013) (113)
- Putting the Patient Back Together - Social Medicine, Network Medicine, and the Limits of Reductionism. (2017) (111)
- Reform, regulation, and pharmaceuticals--the Kefauver-Harris Amendments at 50. (2012) (92)
- An Ethnography of Nonadherence: Culture, Poverty, and Tuberculosis in Urban Bolivia (2004) (83)
- Why do the same drugs look different? Pills, trade dress, and public health. (2011) (74)
- The decline and rise of coronary heart disease: understanding public health catastrophism. (2013) (63)
- Why is there no generic insulin? Historical origins of a modern problem. (2015) (63)
- Attention to ‘Details’: (2004) (62)
- Making medicines essential: The emergent centrality of pharmaceuticals in global health (2011) (54)
- All Health Is Global Health, All Medicine Is Social Medicine: Integrating the Social Sciences Into the Preclinical Curriculum. (2016) (54)
- Pharmaceutical Marketing Research and the Prescribing Physician (2007) (49)
- 2002 Roy Porter Memorial Prize Essay Therapeutic Infidelities: ‘Noncompliance’ Enters the Medical Literature, 1955–1975 (2004) (48)
- Case Studies in Social Medicine - Attending to Structural Forces in Clinical Practice. (2018) (44)
- Attacks on Public Health Officials During COVID-19. (2020) (40)
- Making the Case for History in Medical Education (2015) (40)
- Keeping Modern in Medicine: Pharmaceutical Promotion and Physician Education in Postwar America (2009) (39)
- Combination drugs--hype, harm, and hope. (2011) (39)
- Is Dementia in Decline? Historical Trends and Future Trajectories. (2016) (39)
- Pharmaceutical Marketing and the New Social Media (2010) (36)
- Releasing the Flood Waters: Diuril and the Reshaping of Hypertension (2005) (33)
- A historical perspective of pharmaceutical promotion and physician education. (2008) (33)
- Variations in structure and content of online social networks for patients with diabetes. (2011) (31)
- Generic Drug Approvals Since the 1984 Hatch-Waxman Act. (2016) (30)
- Therapeutic Revolutions: Pharmaceuticals and Social Change in the Twentieth Century (2016) (30)
- Do-It-Yourself Medical Devices--Technology and Empowerment in American Health Care. (2016) (29)
- Misdiagnosis, Mistreatment, and Harm - When Medical Care Ignores Social Forces. (2020) (28)
- Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law. (2017) (24)
- Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America (2012) (24)
- When did medicines become essential? (2010) (22)
- The contributions of prevention and treatment to the decline in cardiovascular mortality: lessons from a forty-year debate. (2012) (22)
- Digital Futures Past - The Long Arc of Big Data in Medicine. (2019) (22)
- Role of the FDA in Affordability of Off-Patent Pharmaceuticals. (2016) (21)
- The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution. (2021) (20)
- Generic: The Unbranding of Modern Medicine (2014) (20)
- The evolving roles of the medical journal. (2012) (19)
- Strategies to improve the affordability of insulin in the USA. (2017) (19)
- Specialized management of the Alzheimer's disease patient: does it make a difference? A preliminary progress report. (1985) (18)
- Therapeutic evolution and the challenge of rational medicine. (2012) (17)
- What’s in a Name?: Generics and the Persistence of the Pharmaceutical Brand in American Medicine (2011) (16)
- Locating global health in social medicine (2014) (15)
- Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status. (2012) (14)
- The substance of the brand (2011) (13)
- The Shared Goals and Distinct Strengths of the Medical Humanities: Can the Sum of the Parts Be Greater Than the Whole? (2017) (13)
- Comparative Effectiveness Research in the US (2009) (11)
- Moneyball and medicine. (2012) (11)
- Reducing Branded Prescription Drug Prices: A Review of Policy Options (2017) (10)
- Clinical Trials, Healthy Controls, and the Birth of the IRB. (2016) (9)
- The Death of Animals in Medical School. (2017) (9)
- Dramatic interventions in the tragedy of the COVID-19 pandemic (2020) (8)
- From Ariadne's Thread to the Labyrinth Itself - Nosology and the Infrastructure of Modern Medicine. (2020) (8)
- A medical student scholarly concentrations program: scholarly self-efficacy and impact on future research activities (2020) (7)
- The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals. (2015) (7)
- The abnormal and the pathological: Cholesterol, statins, and the threshold of disease (2007) (7)
- Preying on Prescribers (and Their Patients) - Pharmaceutical Marketing, Iatrogenic Epidemics, and the Sackler Legacy. (2019) (7)
- Remembering Past Lessons about Structural Racism - Recentering Black Theorists of Health and Society. (2021) (7)
- The materiality of the brand: Form, function, and the pharmaceutical trademark (2013) (6)
- Promise and Peril for Generic Drugs. (2016) (6)
- Insulin for all: treatment activism and the global diabetes crisis (2019) (6)
- From Visible Harm to Relative Risk (2010) (5)
- Introduction: Reimagining Epidemics (2021) (5)
- "For me there is no substitute"-authenticity, uniqueness, and the lessons of lipitor. (2010) (5)
- Risk, responsibility, and generic drugs. (2012) (5)
- Promises and perils of mobile health in Burkina Faso (2021) (5)
- Vital Objects: Essential Drugs and Th eir Critical Legacies (2015) (4)
- The Electronic Health Record and the Clinical Examination. (2018) (4)
- The Death of Animals in Medical School. (2017) (4)
- When Is a Medicine Good Enough?: Science, Similarity, and the History of Generic Drugs (2019) (4)
- Are the Medical Humanities for Sale? Lessons from a Historical Debate (2016) (4)
- Revitalising global social medicine (2021) (3)
- Introduction to Special Issue: Psychiatry as Social Medicine (2021) (3)
- Contingent Knowledge and Looping Effects - A 66-Year-Old Man with PSA-Detected Prostate Cancer and Regrets. (2019) (3)
- Case management in the elderly. (1983) (3)
- Recurring revolutions? tuberculosis treatments in the era of antibiotics (2016) (3)
- Alzheimer's disease: a brief history. (1989) (3)
- Grey-market medicines: diphtheria antitoxin and the decay of biomedical infrastructure (2017) (3)
- 6. Pharmaceutical Geographies: Mapping the Boundaries of the Therapeutic Revolution (2019) (2)
- Drugs and the elderly. (1983) (2)
- How medicine becomes trash: disposability in health care (2022) (2)
- Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis. (2020) (2)
- Amnesia, Adverse Effects, and the Angel of History (2019) (2)
- Origins of the insulin crisis: how a century of price-fixing controversies affects the cost of care today (2021) (2)
- KNOWLEDGE IN MEDIAS RES: TOWARD A MEDIA HISTORY OF SCIENCE, MEDICINE, AND TECHNOLOGY (2020) (2)
- Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes Therapy. (2020) (2)
- Transforming a U.S. scholarly concentrations program internationally: lessons learned (2019) (2)
- Academic-industrial relations before the blockbuster drugs: lessons from the Harvard Committee on Pharmacotherapy, 1939-1943. (2011) (2)
- Low-flow nasal cannula oxygen and potential nosocomial spread of COVID-19 (2020) (1)
- Fairness in drug prices: do economists think differently from the public? (2018) (1)
- Is There a Rosenberg School? (2008) (1)
- Bioethical Issues in Pharmacoepidemiologic Research (2019) (1)
- Swimming Upstream (2012) (1)
- Health care for older citizens: overcoming barriers. (1985) (1)
- Overdiagnosis and overtreatment over time (2015) (1)
- 3. Colonial Medicine and Its Legacies (2019) (1)
- Promoting positive outcomes through geriatric units. Statistical profile of the first 100 patients. (1986) (1)
- Psychotropic drug use in older people: a review. (1985) (1)
- Dementia: physician approach to the caregiver's problems. (1989) (1)
- Is an Ounce of Prevention Worth an Ounce of Cure? Explaining the Decline in Cardiovascular Mortality, 1964-2010 (2011) (0)
- In Reply to Wald. (2018) (0)
- Psychotropic drug use in the nursing home. (1992) (0)
- Tropical diseases in Iowa in the postwar era. (1943) (0)
- Regulating Drugs, Regulating Diseases (2012) (0)
- On Speed: The Many Lives of Amphetamine (review) (2010) (0)
- Regulating Drugs, Regulating Diseases: Consumerism and the US Tolbutamide Controversy (2013) (0)
- Training in geriatric medicine: an unmet need. (1983) (0)
- Notices of Books (1896) (0)
- Fairness in the trade-off between drug price regulation and investments in research and development: A survey of economists (2020) (0)
- Journals under Threat: A Joint Response from History of Science, Technology, and Medicine Editors (2009) (0)
- Competition And Vulnerabilities In The Global Supply Chain For US Generic Active Pharmaceutical Ingredients. (2023) (0)
- The Disappointment of the Biosimilar (2018) (0)
- Diagnostic dilemmas in the nursing home: tracking hidden medical/psychiatric illness. (1992) (0)
- The Republic of Therapy: Triage and Sovereignty in West Africa's Time of AIDS (review) (2012) (0)
- Changing lifestyles to combat osteoporosis. (2001) (0)
- Beyond COVID-19: scaling up and sustaining mobile health in Africa – Authors' reply (2021) (0)
- Books Received (1986) (0)
- Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and Its Consequences (2013) (0)
- Jeremy A. Greene : capstone (2007) (0)
- Is psychiatry an endangered species? (1975) (0)
- Responsibilities of a medical school to a community. (1947) (0)
- Know Your Numbers — At Your Peril Prescribing by Numbers : Drugs and the Defi nition of Disease (2011) (0)
- The geriatric patient: a creative practice approach. (1986) (0)
- The Walking Classroom and the Community Clinic: Teaching Social Medicine Beyond the Medical School (2019) (0)
- A Tribute to Gert Brieger (1932–2021) (2021) (0)
- Introduction: Medicine Made Modern by Medicines (2019) (0)
- Psychopharmacology for non-psychiatrists: a review. (1974) (0)
- The matter of medicine (2017) (0)
- Health Care Access on the Line - Audio-Only Visits and Digitally Inclusive Care. (2022) (0)
- Management of Alzheimer's disease. (1985) (0)
- Therapeutic Proofs and Medical Truths: The Enduring Legacy of Early Modern Drug Trials (2017) (0)
- Evaluation of a multidisciplinary treatment approach in an inpatient geropsychiatric unit. (1994) (0)
- Introduction: Reimagining Epidemics (2021) (0)
- Institutional Reckonings in the History of Medicine (2022) (0)
- Are the Medical Humanities for Sale? Lessons from a Historical Debate (2014) (0)
- Theme Seminar - Program 4 Copenhagen Center for Healthy Aging (2011) (0)
- Diseases: Consumerism and the US Tolbutamide Controversy (2013) (0)
This paper list is powered by the following services:
Other Resources About Jeremy Greene
What Schools Are Affiliated With Jeremy Greene?
Jeremy Greene is affiliated with the following schools:
